Treatment with DHX inhibitor significantly inhibited tumour growth (Extended Data Fig. 10a,c) and prolonged survival (Extended Data Fig. 10e) in the IDH-wild-type, but not the IDH-mutant, group (Extended Data Fig. 10b,d,f). Here, IDH1 is linked to neoplasm.